infectious disease
News/ News/ Sales and Marketing
Sandoz bulks up with Mycamine ahead of spin-off
Phil Taylor
antifungal, Astellas, infectious disease, Novartis, Sales and Marketing, Sandoz
0 Comment
With filing due soon, Moderna stakes a claim to the RSV vaccine market
Phil Taylor
GSK, infectious disease, Moderna, Pfizer, respiratory syncytial virus, vaccine
0 Comment
FDA starts review of Sanofi, AZ antibody for RSV prevention
Phil Taylor
AstraZeneca, infectious disease, nirsevimab, respiratory syncytial virus, Sanofi
0 Comment
mRNA can deliver universal flu vaccine, say US researchers
Phil Taylor
infectious disease, influenza, mRNA, mRNA vaccines, vaccines
0 Comment
News/ News/ Novartis/ R&D/ Top pharmaceutical companies
Novartis, MMV take new malaria drug combination into phase 3
Phil Taylor
Coartem, ganaplacide, infectious disease, Malaria, Novartis, parasitology
0 Comment
As resistant tuberculosis rises, GSK says trial backs novel antibiotic
Phil Taylor
antibiotic, antimicrobial resistance, GlaxoSmithKline, infectious disease, tuberculosis
0 Comment
GSK plans phase 3 for hepatitis B drug bepirovirsen, despite efficacy drop
Phil Taylor
antisense oligonucleotides, bepirovirsen, GlaxoSmithKline, hepatitis B, infectious disease, Ionis Pharmaceuticals
0 Comment
Market Access/ News/ News/ News/ R&D
GSK preps filing for novel antibiotic for urinary tract infections
Phil Taylor
antibiotic, antimicrobial resistance, gepotidacin, GlaxoSmithKline, infectious disease
0 Comment